Rigor Reviewed

Rigor-Reviewed Manuscript

Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial.

Name: Αlpha¹ Rigor Record — Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial.
Item: Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial.
Rating: 59
Author: Αlpha¹

Glue P, Loo C, Fam J, Lane HY, Young AH, Surman P, BEDROC study investigators

Paper source

Read full text (PMC)

Embed this Rigor badge

Αlpha¹ Rigor Review — 3★ (Adequate), 0 critical, 2 high issues for “Extended-release ketamine tablets for treatment-resistant depression: a randomized placebo-controlled phase 2 trial.”

Links back to this Rigor Record.

Αlpha¹ Editorial

This rigor review was examined and confirmed by Αlpha¹ Editorial · August 16, 2026

Αlpha¹ Rigor Review

Rigor Reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern−0.5★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★
StatisticsPrinted percentage does not match its own count (capped)−0.25★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 10 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Problems surfaced6 types

Numerical inconsistencies2

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Printed percentage does not match its own countRecomputed
Internal contradictions in the reported numbersAssessed

Overstated conclusions3

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed
Conclusions only partially backed by the presented evidenceAssessed

Reporting gaps1

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

This Αlpha¹ Rigor Review uses AI Rigor Reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted phase 2 randomized placebo-controlled trial with rigorous design, clear reporting, and appropriate statistical methods. The main weaknesses are a vague data availability statement and the lack of named statistical software, both minor reporting gaps. The copyedit issues are minor typos and consistency problems.

Both reviewers agreed on all dimensions and study type (interventional). The statistics verification component checked only 4 tests (3 consistent, 1 inconsistent) and cannot verify threshold-only p-values or resampling-based tests; the inconsistent test is not specified and does not constitute a demonstrable error. The integrity concern about the wide CI is low severity and not a validity threat.

9 major claims checked against the paper's own evidence: 2 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Recomputed 3 tests: 3 consistent, 0 inconsistent; 3 via agent-written checks. 1 printed percentage that does not match its own count.

1 integrity concern flagged (0 high).

Reporting

Eight Dimensions7 pass · 1 warn

The introduction cites prior research on ketamine's antidepressant effects, oral dosing, and the prodrug hypothesis, and explains the rationale for an extended-release formulation. It also addresses limitations of prior work, such as high failure rates in acute trials and the need for enrichment designs. The hypothesis follows logically from the cited evidence.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise with extensive prior work and a logical rationale for the study hypothesis.

Evidence

paraphrase[Introduction, paragraph 1]

“A meta-analysis of ketamine formulations identified that formulations that maximize first-pass metabolism of ketamine and delay time to maximum concentrations were better tolerated (less dissociation) and safer (less blood pressure change) than formulations that lack those characteristics.”

direct quote[Introduction, paragraph 3]

“We chose this design owing to observations that acute antidepressant clinical trials in non-TRD depression have high failure rates (inability to separate clinical response between active and placebo arms), as high as 50% (refs. , ).”